The M3810A Philips TeleMonitoring System with eDevice BridgeD130 is intended to be used upon prescription of a licensed physician or authorized healthcare provider by patients as a means to automatically collect and transmit medical information, such as weight, blood pressure, and non-diagnostic ECG, over normal residential telephone lines or cellular connectivity, between a patient, typically at home, and a health care professional at the authorized provider. The device does not send any real-time alarms. Clinical judgment and experience are required to check and interpret the information delivered.

The M3810A Philips TeleMonitoring System with eDevice BridgeD130 is indicated for patients at home, who are capable and willing to self administrate this device, upon the prescription of their healthcare provider, to collect and transmit medical information such as weight, blood pressure (including pulse rate) and non-diagnostic ECG rhythm strip to the healthcare provider at another location. The patient takes these measurements, typically once per day, and the information is transmitted automatically via normal telephone lines or cellular connectivity to the healthcare provider. The device may be used for the management of congestive heart failure, hypertension, ischemic heart disease, weight management, cardiovascular risk management, post cardiovascular surgery, post myocardial infarction, and other post cardiac events. The device does not send any real time alarms. Clinical judgment and experience are required to check and interpret the information delivered.

Device Description

The M3810A Philips Telemonitoring System with eDevice BridgeD130 is a system that automatically collects and transmits medical information such as weight, blood pressure, and non-diagnostic ECG from a patient at home to a healthcare professional. The eDevice BridgeD130 is an external wireless communication device that transmits data to the backend clinical server.

AI/ML Overview

The provided text describes a 510(k) premarket notification for the "M3810A Philips Telemonitoring System with eDevice BridgeD130". The primary modification is the addition of a wireless communication option (eDevice BridgeD130) to transmit data.

Based on the provided information, I can answer some of your questions, but it's important to note that this document is a 510(k) summary for a modification of an existing device. As such, the performance data presented focuses on demonstrating that the modified device maintains substantial equivalence to the predicate device, rather than providing an exhaustive de novo performance study.

Here's the breakdown of the information you requested:

1. Table of Acceptance Criteria and Reported Device Performance

The document broadly states: "Acceptance criteria were based on the specification cleared for the predicate device, the specifications of the subject device and test results showed substantial equivalence." It does not provide a specific table with quantitative acceptance criteria and corresponding performance metrics for individual parameters (like blood pressure accuracy or ECG interpretation accuracy).

Instead, it refers to broad categories of testing and general compliance:

Acceptance Criteria (Implied)	Reported Device Performance
Specifications cleared for the predicate device	Test results showed substantial equivalence
Specifications of the subject device (M3810A + eDevice BridgeD130)	Test results showed substantial equivalence
Compliance with applicable standards	Completed electrical safety testing, EMC testing, mechanical durability, safety (operator and patient), temperature/humidity and radio telemetry testing and user evaluations for consumer accuracy demonstrated compliance with applicable standards.
Reliability requirements and performance claims	Meets all reliability requirements and performance claims

2. Sample Size Used for the Test Set and Data Provenance

The document does not explicitly state the sample size used for the test set or the data provenance (country of origin, retrospective/prospective). The testing focused on functional verification and validation of the hardware and software changes, not a clinical trial with a patient population.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications

This information is not provided. The study described is a technical verification and validation, not a clinical study requiring expert ground truth for interpretation of physiological data in a clinical context. The device collects non-diagnostic ECG and other physiological data, which are then interpreted by a healthcare professional.

4. Adjudication Method for the Test Set

This information is not provided because the testing described is not a clinical study involving human interpretation needing adjudication.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No. The document describes technical verification and validation, not a comparative effectiveness study involving human readers with and without AI assistance. The device is for data collection and transmission, not for automated interpretation or diagnosis.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

The device itself is a data collection and transmission system. The "algorithm" in this context refers to the system's ability to accurately acquire and transmit data. The performance claims are related to the accuracy of the measurements and the reliability of the transmission, which are evaluated in a standalone manner (device functioning correctly) but don't involve an "algorithm" in the sense of AI for image or signal interpretation. The document states: "The device does not send any real-time alarms. Clinical judgment and experience are required to check and interpret the information delivered." This clearly indicates it's not a standalone diagnostic algorithm.

7. The Type of Ground Truth Used

For the instrumentation itself (weight, blood pressure, ECG signal acquisition), the "ground truth" would be established by reference standards or highly accurate laboratory equipment during calibration and functional testing. For example, blood pressure monitors are often tested against mercury sphygmomanometers, or using pressure simulators. ECG acquisition would be verified against known signal inputs. The document generally refers to "specifications," implying that performance was measured against predetermined engineering or regulatory benchmarks.

8. The Sample Size for the Training Set

No training set is mentioned or applicable in the context of this device. This is not an AI/machine learning device that learns from a training set. It is a physiological monitoring and transmission system.

9. How the Ground Truth for the Training Set Was Established

Not applicable, as there is no training set for this device.

Summary

{0}------------------------------------------------

Section 510 (K) Summary

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 CFR 807-92(c).

The submitter of this pre-market notification is: Carlos O. Acosta Philips Lifeline 111 Lawrence Street. Framingham, MA 01702-8156 Tel: 508-988-1366 Fax: 508-988-1015 Email: carlos.acosta1@philips.com

DEC 1 2010

Alternate contact: David R. Jones Philips Home Monitoring 111 Lawrence Street, Framingham, MA 01702-8156 Tel: 508-988-1658 Fax: 508-988-1015 Email: david.r.jones@philips.com

Date of summary	Thursday, October 28, 2010
Device name	The M3810A Philips Telemonitoring System with eDeviceBridgeD130

Common name Physiological Transmitter and Receiver.

Classification names are as follows:

Classification Name	RegulationNumber	ProCode
Physiological Signal Transmitters and Receivers	870.2910	DRG
Non-invasive Blood Pressure	870.1130	DXN
Electrograph	870.2340	DPS
Patient scale	870.2720	FRW
Oximeter	870.2700	DQA
Glucose Test System	862.1345	CGA

Predicate Devices

The modified device is substantially equivalent to the previously cleared Modification of Physiological Signal Transmitter & Receiver pursuant to K993169 (September 22, 1999).

Confidential

Page 55 of 75

{1}------------------------------------------------

K103214 P2/2

HILIPS

Modifications The addition of the eDevice BridgeD130 wireless communication option to transmit data to the backend clinical server. This device is substantially equivalent to the previous cleared Honeywell HomMedtGenesis DM Remote Patient Care Monitor K101242, the difference between the two devices is that the eDevice BridgeD130 is an external communication device and the Honeywell HomMedtGenesis DM Remote Patient Care Monitor is an internal communication module.

Intended Use The subject device has the same intended use and indications for use as the legally marketed predicate devices with the addition of wireless communication option:

The M3810A Philips TeleMonitoring System with eDevice BridgeD130 is intended to be used upon prescription of a licensed physician or authorized healthcare provider by patients as a means to automatically collect and transmit medical information, such as weight, blood pressure, and non-diagnostic ECG, over normal residential telephone lines or cellular connectivity, between a patient, typically at home, and a health care professional at the authorized provider. The device does not send any real-time alarms. Clinical judgment and experience are required to check and interpret the information delivered.

Technological The modify device has the same fundamental technological characteristics characteristics as the legally marketed predicate device.

Performance data Verification, validation, and testing activities were conducted to establish the performance, functionality, and reliability characteristics of the subject devices with respect to the predicates. Testing involved level tests, functionality/performance tests, software and safety testing from hazard/risk analysis. Completed electrical safety testing, EMC testing, mechanical durability, safety (operator and patient), temperature/humidity and radio telemetry testing and user evaluations for consumer accuracy demonstrated compliance with applicable standards. Acceptance criteria were based on the specification cleared for the predicate device, the specifications of the subject device and test results showed substantial equivalence. The results demonstrate that the M3810A Philips Telemonitoring System with the addition of a cellular connectivity device meets all reliability requirements and performance claims and supports a determination of substantial equivalence.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes coiled around it, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged in a circular pattern around the symbol. The logo is black and white.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

DEC 1 2010

Lifeline Systems, Inc. Philips Medical Systems North America, Co. c/o Mr. Carlos O. Acosta Sr. Quality Assurance & Regulatory Manager 111 Lawrence Street, Framingham, MA 01702-8156

Re: K103214

Trade/Device Name: M3810A Philips Telemonitoring System with eDevice BridgeD130 Regulation Number: 21 CFR 870.2910 Regulation Name: Physiological Signal Transmitters and Receivers Regulatory Class: Class II (two) Product Code: DRG Dated: October 28, 2010 Received: November 1, 2010

Dear Mr. Acosta:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{3}------------------------------------------------

Page 2 -- Mr. Carlos O. Acosta

Please be advised that FDA 's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

Bram D. Zuckerman, M.D.

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

PHILIPS

3.2 Indications for Use KI03214 510 (k) Number (if known):

DEC 1 2010

Device Name: M3810A Philips Telemonitoring System with eDevice BridgeD130

Prescription Use: YES AND/OR over-the-counter Use: NO (Part 21 CFFR 801 Subpart D) (21 CFR 807 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of 1

(Division Sign-Off)
Division of Cardiovascular Devices
510(k) Number K103214

Confidential

Page 26 of 75

Regulation Number and Section

§ 870.2910 Radiofrequency physiological signal transmitter and receiver.

(a)
Identification. A radiofrequency physiological signal transmitter and receiver is a device used to condition a physiological signal so that it can be transmitted via radiofrequency from one location to another, e.g., a central monitoring station. The received signal is reconditioned by the device into its original format so that it can be displayed.(b)
Classification. Class II (performance standards).